Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial.
Venkatesh N
VN
Prajna
Prajna S
PS
Lalitha
Jeena
J
Mascarenhas
Tiruvengada
T
Krishnan
Muthiah
M
Srinivasan
C M
CM
Vaitilingam
Catherine E
CE
Oldenburg
Aileen
A
Sy
Jeremy David
JD
Keenan
Travis C
TC
Porco
Nisha R
NR
Acharya
Thomas M
TM
Lietman
D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D001230:Aspergillus / Q000302:isolation & purification*; D015821:Eye Infections, Fungal / Q000188:drug therapy* / Q000382:microbiology; D060585:Fusariosis / Q000188:drug therapy / Q000382:microbiology; D005670:Fusarium / Q000302:isolation & purification*; D006801:Humans; D007634:Keratitis / Q000188:drug therapy* / Q000382:microbiology; D010866:Natamycin / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D010866:Natamycin; D065819:Voriconazole